Update of REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line (2L) treatment of stage IV non-small cell lung cancer (NSCLC) including subgroup analysis of histology

Exploratory subgroup analysis of patients (Pts) refractory to first-line (1L) chemotherapy from REVEL, a randomized phase III study of docetaxel (DOC) with ramucirumab (RAM) or placebo (PBO) for second-line (2L) treatment of stage IV non-small-cell lung cancer (NSCLC).

10.1200/jco.2016.34.15_suppl.9079 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 9079-9079 ◽

Cited By ~ 3

Author(s):

Martin Reck ◽

Luis G. Paz-Ares ◽

Paolo Bidoli ◽

Federico Cappuzzo ◽

Shaker R. Dakhil ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Subgroup Analysis ◽

Stage Iv ◽

Small Cell ◽

Phase Iii ◽

Second Line ◽

Small Cell Lung ◽

First Line ◽

REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease progression after one prior platinum-based therapy.

10.1200/jco.2014.32.15_suppl.lba8006 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. LBA8006-LBA8006 ◽

Cited By ~ 2

Author(s):

Maurice Perol ◽

Tudor-Eliade Ciuleanu ◽

Oscar Arrieta ◽

Kumar Prabhash ◽

Konstantinos N. Syrigos ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Stage Iv ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Second Line ◽

Small Cell Lung ◽

Double Blind ◽

A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS)

Lung Cancer ◽

10.1016/j.lungcan.2016.06.019 ◽

2016 ◽

Vol 99 ◽

pp. 94-101 ◽

Cited By ~ 7

Author(s):

Egbert F. Smit ◽

Yi-Long Wu ◽

Radj Gervais ◽

Caicun Zhou ◽

Enriqueta Felip ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Second Line ◽

Small Cell Lung ◽

Double Blind ◽

Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer

Lung Cancer ◽

10.1016/j.lungcan.2017.07.038 ◽

2017 ◽

Vol 112 ◽

pp. 181-187 ◽

Cited By ~ 20

Author(s):

Martin Reck ◽

Luis Paz-Ares ◽

Paolo Bidoli ◽

Federico Cappuzzo ◽

Shaker Dakhil ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Stage Iv ◽

Small Cell ◽

Phase Iii ◽

Refractory Disease ◽

Line Treatment ◽

Second Line ◽

Small Cell Lung ◽

A Randomized, Double-Blind, Phase III Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non–Small-Cell Lung Cancer After Disease Progression After 1 Previous Platinum-Based Therapy (REVEL): Treatment Rationale and Study Design

Clinical Lung Cancer ◽

10.1016/j.cllc.2012.06.007 ◽

2012 ◽

Vol 13 (6) ◽

pp. 505-509 ◽

Cited By ~ 24

Author(s):

Edward B. Garon ◽

Dachuang Cao ◽

Ekaterine Alexandris ◽

William J. John ◽

Sergey Yurasov ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Disease Progression ◽

Study Design ◽

Stage Iv ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Double Blind ◽

Efficacy and safety results from CurrentS, a double-blind, randomized, phase III study of second-line erlotinib (150 mg versus 300 mg) in current smokers with advanced non-small cell lung cancer (NSCLC).

10.1200/jco.2014.32.15_suppl.8046 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 8046-8046 ◽

Cited By ~ 1

Author(s):

Egbert F. Smit ◽

Radj Gervais ◽

Caicun Zhou ◽

Enriqueta Felip ◽

Ji Feng Feng ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Second Line ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Double Blind ◽

Exploratory analysis of safety by histology and efficacy in a nonsquamous NSCLC subgroup in REVEL: A randomized phase III study of ramucirumab (RAM) plus docetaxel (DOC) vs DOC for second-line treatment of stage IV non-small-cell lung cancer (NSCLC).

10.1200/jco.2015.33.15_suppl.8055 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 8055-8055 ◽

Cited By ~ 3

Author(s):

Luis Paz-Ares ◽

Maurice Perol ◽

Tudor-Eliade Ciuleanu ◽

Ruben Dario Kowalyszyn ◽

Martin Reck ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Stage Iv ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Second Line ◽

Small Cell Lung ◽

Phase Iii Study ◽

Nonsquamous Nsclc

A Randomized, Double-blind, Placebo‑Controlled Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy (Carboplatin- Etoposide) in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Case Medical Research ◽

10.31525/ct1-nct04063163 ◽

2019 ◽

Author(s):

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Iii Study ◽

Extensive Stage

Faculty Opinions recommendation of Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718451079.793497341 ◽

2014 ◽

Author(s):

Laurie Carr

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Disease Progression ◽

Stage Iv ◽

Small Cell ◽

Line Treatment ◽

Second Line ◽

Small Cell Lung ◽

Phase 3 ◽

Double Blind

Phase III study in stage IV non-small-cell lung cancer patients treated with two courses of cisplatin/gemcitabine followed by a randomization to three additional courses of the same combination or gemcitabine alone

Annals of Oncology ◽

10.1093/annonc/mdm061 ◽

2007 ◽

Vol 18 (5) ◽

pp. 903-908 ◽

Cited By ~ 14

Author(s):

S. Novello ◽

P. Bruzzi ◽

C. Barone ◽

R. Buosi ◽

A. Masotti ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cancer Patients ◽

Cell Lung Cancer ◽

Stage Iv ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Lung Cancer Patients ◽